TODAY'S MARKET INTELLIGENCE
Shutaishen: Subsidiary's STSP-0601 Gains U.S. FDA Clinical Trial Approval
English summary
Shutaishen announced that its subsidiary Beijietai received FDA approval to conduct clinical trials of STSP-0601 for bleeding in hemophilia A or B patients with inhibitors. The drug was registered with China's NMPA in June 2026.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence